DEXCOM INC
DXCMNASDAQTrading Snapshot
- Day Range
- $85.65 β $87.63
- 52-Week Range
- $54.11 β $92.59
- Volume
- $2.66B
- Avg Volume
- $2.72B
- Shares Outstanding
- 377.4M
- Next Earnings
- Nov 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $4.66B
- Last Q Revenue
- $1.31B
- P/E Ratio
- 33.4
- P/S Ratio
- 6.6x
- EPS (TTM)
- $2.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β1.9%
Why Investors Own DXCM
- βHigh-growth profile β revenue up +38.6% YoY with expanding US Equity exposure.
- βHealthy economics β 76% gross margin and 8% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
DEXCOM INC
DXCM
StockOtter Β· stockotter.spaceAbout DEXCOM INC
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
Here's Why DexCom (DXCM) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
[url="]DexCom, Inc.[/url] (NASDAQ: DXCM), the global leader in glucose biosensing, today released its Γ’ΒΒDexcom State of Type 2 Report: Global Access and Attitu
DexCom, Inc. (NASDAQ:DXCM) Stock Rated βModerate Buyβ by Wall Street Brokerages
DexCom, Inc. (NASDAQ: DXCM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst ha
Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.